– Renowned Medical Specialist to Address Ongoing Challenges in Managing LDL-Cholesterol for Cardiovascular Disease Prevention –
ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion ESPR today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe).
The event will be hosted by LeAnne Bloedon, Vice President and Head of Clinical Development at Esperion, and will include a conversation with:
Patrick Moriarty, M.D., Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center.
Registration for the KOL webinar can be found here. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company in the commercial stage dedicated to introducing innovative medications that meet the unmet needs of patients and healthcare providers. The company has developed and is marketing the only oral, once-daily, non-statin treatments approved by the U.S. Food and Drug Administration (FDA) for patients at risk of cardiovascular disease who have high levels of low-density lipoprotein cholesterol (LDL-C). These treatments are backed by the substantial data from the CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients. Esperion is also advancing its next-generation program aimed at creating ATP citrate lyase inhibitors (ACLYi). Recent advancements in understanding the structure and function of ACLYi facilitate targeted drug design, allowing for the development of highly effective and specific inhibitors utilizing allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.
Esperion Contact Details:
Investors:
Alina Venezia
(734) 887-3903
Media:
Tiffany Aldrich
(616) 443-8438
